This article first appeared on GuruFocus .
-
GAAP Loss:$122 million or negative $1.95 per share for Q2 2026.
-
Book Value:$10.24 per share as of June 30, 2026.
-
Distributable Loss:$36 million or negative $0.58 per share.
-
Distributable Earnings Before Realized Losses:$6 million or $0.10 per share.
-
Cash Dividend:$0.10 per share for the second quarter.
-
Legacy Office Exposure:Declined to 18% of the portfolio as of June 30, 2026.
-
Watch List:Represents 16% of the portfolio as of June 30, 2026.
-
Life Science Exposure:Modified approximately 39% of exposure.
-
New Originations:Loans from 2024-2026 represent 32% of the portfolio.
-
Repayments:Over $800 million received during the quarter; expecting over $2 billion for 2026.
-
Common Stock Repurchase:$38 million repurchased at $6.63 per share; additional $10 million at $7.24 per share post-quarter.
-
Liquidity:Over $700 million, including $83 million cash on hand and $350 million undrawn capacity.
-
Total Financing Availability:$7 billion, with $2.6 billion undrawn capacity.
-
Debt-to-Equity Ratio:2.6 times as of quarter end.
-
Total Leverage:4.3 times as of quarter end.
Release Date: July 22, 2026
For the complete transcript of the earnings call, please refer to the full earnings call transcript .
Positive Points
-
KKR Real Estate Finance Trust Inc ( NYSE:KREF ) reported distributable earnings before realized losses of $0.10 per share, covering their quarterly dividend.
-
The company has made significant progress in reducing legacy office exposure, which declined to 18% of the portfolio from 21% at the end of 2025.
-
KREF received over $800 million in repayments during the quarter, contributing to a strong liquidity position with over $700 million available.
-
The company repurchased $38 million of common stock, generating approximately $0.32 per share of book value accretion.
-
KREF originated three new loans totaling approximately $350 million, with a weighted average loan-to-value (LTV) of 58%, indicating disciplined capital deployment.
Negative Points
-
KKR Real Estate Finance Trust Inc ( NYSE:KREF ) reported a GAAP loss of $122 million or negative $1.95 per share for the second quarter of 2026.
-
Book value declined by 13.7% during the quarter, primarily due to actions taken to position watchlist assets and legacy office exposures for monetization.
-
The watchlist represents 16% of the portfolio, with nearly half of the assets currently being marketed, indicating ongoing challenges in asset resolution.
-
The company downgraded several loans, including the Chicago office and Carrollton multifamily loans, reflecting current market conditions.
-
KREF's debt-to-equity ratio was 2.6 times, with total leverage at 4.3 times, slightly above their target leverage range of 3.5 to 4 times.
Q & A Highlights
Q: How was the loan loss review process and book value assessment different this quarter compared to the previous two quarters? A: The decline in book value this quarter reflects the current expectations for monetization of watchlist assets. The process involves discovering clearing values and market conditions. While there could be minor fluctuations, the most significant book value impact is believed to be behind us. (Matthew Salem, CEO)
Q: How are capital allocation priorities ranked for the rest of the year, especially with the level of repayments? A: The focus will be on maintaining leverage ratios, with a temporary pause on new originations due to current leverage levels. Share buybacks have been accretive, but future decisions will involve the strategic review committee. Regular investing will continue, keeping leverage ratios in mind. (Matthew Salem, CEO)
Q: Can you provide an update on the RISC-5 Boston Life Science loan? A: We are in modification discussions and believe we are fully reserved on that loan. It is not anticipated to have negative book value implications going forward. (Unidentified Respondent)
Q: What are the broader credit trends in multifamily, given the current commercial real estate cycle? A: The higher rate environment has put pressure on values, but the impact on credit risk or loss content in multifamily is not expected to be material. There is optimism for tightening in rents and occupancy in the coming quarters, despite current softness. (Matthew Salem, CEO)
Q: Is KREF able to buy back stock during the strategic review process? A: The strategic review does not preclude stock buybacks, but it will be a conversation with the committee as part of the overall capital use strategy. (Matthew Salem, CEO)
Q: How are spreads on new loans compared to what is paying off, given the elevated repayments? A: Spreads on new loans are lower due to adjustments for the current rate environment. However, the return on equity remains consistent in the low double-digit range, around 12%. (Unidentified Respondent)
Q: What is the expected duration for the remaining REO book, and is there a strategy to accelerate selling? A: The REO portfolio is categorized into near-term, medium-term, and longer-term resolutions. While some assets are expected to be resolved soon, others, like the Seattle and Boston Life Science assets, will take longer. The strategic review committee may explore options to accelerate sales. (Unidentified Respondent)
Q: What are you seeing across the rest of the life science book, particularly in markets like Cambridge and San Carlos? A: There are early signs of recovery in life science markets, with some leasing activity. West Coast markets are seeing more office demand, which is beneficial. However, it is still early for a full recovery in life science. (Unidentified Respondent)
For the complete transcript of the earnings call, please refer to the full earnings call transcript .
